Morgan Stanley Maintains Catalent (CTLT) Overweight Recommendation
2023-05-23 14:38
US
Fintel reports that on May 23, 2023, Morgan Stanley maintained coverage of Catalent (NYSE:CTLT) with a Overweight recommendation.
Analyst Price Forecast Suggests 59.30% Upside
As of May 11, 2023, the average one-year price target for Catalent is 59.75. The forecasts range from a low of 28.28 to a high of $90.30. The average price target represents an increase of 59.30% from its latest reported closing price of 37.51.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Catalent is 4,801MM, an increase of 0.92%. The projected annual non-GAAP EPS is 3.30.
What is the Fund Sentiment?
There are 1253 funds or institutions reporting positions in Catalent.
This is an increase
of
36
owner(s) or 2.96% in the last quarter.
Average portfolio weight of all funds dedicated to CTLT is 0.25%,
a decrease
of 1.98%.
Total shares owned by institutions increased
in the last three months by 2.69% to 236,771K shares.
The put/call ratio of CTLT is 0.39, indicating a
bullish
outlook.
What are Other Shareholders Doing?
Capital World Investors holds 13,404K shares representing 7.44% ownership of the company. In it's prior filing, the firm reported owning 13,817K shares, representing a decrease of 3.09%. The firm increased its portfolio allocation in CTLT by 37.32% over the last quarter.
T. Rowe Price Investment Management holds 12,024K shares representing 6.68% ownership of the company. In it's prior filing, the firm reported owning 16,579K shares, representing a decrease of 37.89%. The firm decreased its portfolio allocation in CTLT by 1.07% over the last quarter.
Janus Henderson Group holds 12,016K shares representing 6.67% ownership of the company. In it's prior filing, the firm reported owning 8,216K shares, representing an increase of 31.63%. The firm decreased its portfolio allocation in CTLT by 34.73% over the last quarter.
Artisan Partners Limited Partnership holds 7,738K shares representing 4.30% ownership of the company. In it's prior filing, the firm reported owning 7,842K shares, representing a decrease of 1.35%. The firm increased its portfolio allocation in CTLT by 34.00% over the last quarter.
Veritas Asset Management LLP holds 6,885K shares representing 3.82% ownership of the company. In it's prior filing, the firm reported owning 11,170K shares, representing a decrease of 62.23%. The firm decreased its portfolio allocation in CTLT by 18.79% over the last quarter.
Catalent Background Information
(This description is provided by the company.)
Catalent, Inc., an S&P 500® Company, is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 14,000 people, including over 2,400 scientists and technicians, at more than 40 facilities across four continents, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey.
Key filings for this company:
